Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized trial of Revatio in congenital heart disease with pulmonary hypertension
2011-005440-98Phase 3Completed
- Sponsor
- Kepler Universitätsklinikum
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sildenafil in pulmonary arterial hypertension (PAH), Ventricular Septal Defect (VSD), atrioventricular canal defect (AVSD) and 1 more (2 arms), sponsored by Kepler Universitätsklinikum. Primary endpoint: number of pulmonary hypertensive crises. Started Mar 2012; status: completed.
02
Drugs
sildenafil
03
Conditions
pulmonary arterial hypertension (PAH)Ventricular Septal Defect (VSD)atrioventricular canal defect (AVSD)Cardiovascular Malformation (CVM)
Beyond the preview
Go deeper on 2011-005440-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005440-98.